Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2019 financial results on Thursday, February 6, 2020 after the close of financial markets.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, January 21, 2020
Information
Tags: 
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Seattle Genetics, Monoclonal antibodies, Takeda Pharmaceutical Company, Medical specialties, CD30, Brentuximab vedotin, Lymphoma, Neoplasms, Clinical medicine, Bothell, Washington, Transitional cell carcinoma, NASDAQ
Geotags: 
WASHINGTON, United States
⚠ generated by AI ↴
Organisation: 
SEATTLE GENETICS
Summary
Key Points: 
  • Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2019 financial results on Thursday, February 6, 2020 after the close of financial markets.
  • Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
  • ADCETRIS is approved for the treatment of several types of CD30-expressing lymphomas, and PADCEV is approved to treat adults with metastatic urothelial cancer.
  • The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union.


Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2019 financial results on Thursday, February 6, 2020 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Thursday, February 6, 2020

1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

REPLAY access

  • Telephone replay will be available beginning at approximately 4:30 p.m. PT on Thursday, February 6, 2020 through 5:00 p.m. PT on Sunday, February 9, 2020 by calling 888-203-1112 (domestic) or +1 719-457-0820 (international); conference ID 7290215
  • Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors section

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the company’s industry-leading antibody-drug conjugate (ADC) technology designed to bring a powerful medicine directly to cancer cells. ADCETRIS is approved for the treatment of several types of CD30-expressing lymphomas, and PADCEV is approved to treat adults with metastatic urothelial cancer. In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer, and in clinical development for metastatic colorectal cancer. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Copyright: 
Copyright Business Wire 2020